Using a risk assessment tool researchers at @cam.ac.uk and @icr.ac.uk have found that NICE referral criteria miss up to 95% of women under 50 who go on to develop breast cancer within 10 years. 🔗 zurl.co/6NNxS @cancerresearchuk.org @breastcancernow.bsky.social

Happy that our most recent paper on nucleotide excision repair mechanisms has now been published in Science Advances. This project was led by @natalia-mg.bsky.social and @callumhaste.bsky.social and focused on visualising early steps of the NER process by #cryoEM. www.science.org/doi/10.1126/...

Visualization of stepwise derepression of TFIIH in global genome nucleotide excision repair

Cryogenic electron microscopy captures nucleotide excision repair complexes assembling on damaged DNA templates.

science.org

🧬 25 years ago, the first draft of the human genome was published, a momentous scientific achievement opening up huge potential for drug discovery. On its anniversary, how far have we come?

We are looking for a Computational Chemist to join our Centre for Protein Degradation at the ICR @icr.ac.uk 📅 Application deadline: 31-July-2026 🔗 Learn more and apply here: jobs.icr.ac.uk/vacancies/15... #hiring #compchem #computationalchemistry #CADD #drugdiscovery #TPD #proteindegradation

Computational Chemist in Sutton | The Institute of Cancer Research

View details and apply for this Computational Chemist vacancy in Sutton. Salary : £50,825 - £53,500 per annum. Commencement on the salary range is subject to comparable skills and experience...

jobs.icr.ac.uk

🖥️ An ultrasound technology pioneered at the ICR to treat tumours without the need for surgery has successfully been adapted and used to treat a serious pregnancy condition. High intensity focused ultrasound (HIFU) uses targeted sound waves to heat and destroy cells inside the body.

📰 In our latest feature, ICR's Professor Anguraj Sadanandam explains how his pioneering research is combining #AI, advanced diagnostics and innovative preclinical models to better understand #BowelCancer and help develop more personalised treatments.

📢 New @fda.gov approval for #capivasertib in advanced #ProstateCancer. The drug, made possible by decades of research at the ICR, helps delay progression in patients with PTEN-deficient disease – an aggressive form with poor outcomes. Read more ⤵️ www.icr.ac.uk/about-us/icr...

ICR welcomes FDA approval of capivasertib for advanced prostate cancer

ICR welcomes FDA approval of capivasertib for advanced prostate cancer

icr.ac.uk

🎤 We’re delighted that ICR's Professor Paul Workman is speaking on a panel today at The Galien Foundation Forum at the @sciencemuseum.org.uk where this year’s focus is Future Health Disrupted: From Discovery to Delivery.

🎙️ICR's Professor Kevin Harrington spoke to Naga Munchetty and Chris Smith on @bbc5live.bsky.social He spoke about how the early discoveries were made that viruses could infect tumours, and how this has led to modern, genetically engineered viruses to treat cancer - called oncolytic virotherapy.

UK research shows cancer trials may be unintentionally excluding some of the patients who could benefit most. From explicit criteria like HIV status to less visible barriers like language, access isn’t always equal. Rethinking trial design is key to making research more inclusive and effective.

New findings from the OrigAMI-4, a study led by Professor Kevin Harrington in advanced head and neck cancer are presented today at #ASCO2026 ⤵️ www.asco.org/abstracts-pr...

At #ASCO2026 in Chicago, results are shared from Professor Robin Jones's study which explores a new drug for advanced GIST and how patients respond.

Also this morning at #ASCO2026, Professor James Larkin is presenting his findings from the RAMPART trial, a phase 3 study comparing durvalumab monotherapy with active monitoring after #KidneyCancer surgery ⬇️ www.asco.org/abstracts-pr...

We're delighted to have researchers from the ICR and The Royal Marsden participating in #ASCO2026 in Chicago. First up today, @prof-nick-james.bsky.social shares findings from the RAD-IO trial, a multi-stage study in #BladderCancer.

🚨 New results published recently in @thelancetoncol.bsky.social show one-week radiotherapy is as safe and effective as the traditional three-week course for early-stage breast cancer.

🚨@pintofscience.uk begins today! We’re kicking off our Pint of Science events in the Prince Albert pub in Battersea. 🧬 Tonight’s sold-out event features ICR scientists @ioannastefani.bsky.social and Jessica Beecroft. #Pint26

Are you attending the annual @estroradiotherapy.bsky.social congress this weekend? Researchers are presenting 8 different trials managed by the ICR’s Clinical Trials and Statistics Unit. ICR's Professor @profemmahall.bsky.social shares her thoughts ahead of the event ⬇️ #ESTRO26

🧬 Lobular #BreastCancer behaves differently from other breast cancers especially once it spreads yet treatment options are still limited.

📢 New research details how an important cellular enzyme is controlled, uncovering new insights into the fundamental biological processes controlling gene expression.

If you are interested in PARP inhibitors and history, this might be of interest to you. www.nature.com/articles/s41.... An attempt to cover the work of thousands and their immense contributions to the development of a targeted approach to treating cancers.

Two decades of PARP inhibitor synthetic lethality in cancer - Nature

The past two decades of PARP inhibitor synthetic lethality in cancer is explored.

nature.com

A new trial design framework for incorporating patient-reported outcomes into dose-optimisation trials "PRO-ADD (Patient-Reported Outcomes Aided Dose-optimisation Design)" is now published in Statistical Methods in Medical Research: journals.sagepub.com/doi/full/10....

PRO-ADD: Patient-empowered dose-finding trials integrating safety, preliminary efficacy and patient-reported outcomes for optimal dose selection - Emily Alger, Sumithra J Mandrekar, Jun Yin, Christina...

Advances in oncology drug development are driving the emergence of novel therapies, challenging traditional dose-efficacy assumptions in dose-finding oncology t...

journals.sagepub.com

In colon, stem cells divide & so do the crypts they reside in: a multi-level evolutionary process. D Mallo, P Bousquets @heathergrant.bsky.social @calumgabbutt.bsky.social have made "PhyPhum" to lineage trace somatic evolution in human glandular tissues www.biorxiv.org/content/10.6... @icr.ac.uk

The intersection of the PI3K/AKT pathway and immunotherapy. ICECAP study led by Prof Juanita Lopez. pubmed.ncbi.nlm.nih.gov/42043781/ @icr.ac.uk @icrdduiit.bsky.social @icr-ctsu.bsky.social @royalmarsden.org @crukconvergence.bsky.social @ecmc-uk.bsky.social @nihr.bsky.social

We're celebrating International Day of Immunology today! We're sharing a video by Ricardo Sainz, a Higher Scientific Officer and PhD Student in Radiation Oncology and Tumour Immunology, who shares his research and why #Immunology is important in #CancerResearch ⤵️ #ImmunoSky #DayOfImmunology

🚨 Early‑onset #BowelCancer is rising and excess weight is part of the story. But new research shows BMI alone can’t explain the full increase in younger adults, pointing to other biological and environmental factors we still need to understand. Tackling obesity must become a national priority.

Sophie was diagnosed with stage 4 bowel cancer at the age of 36. Five years on, thanks to an experimental immunotherapy trial, she now has no evidence of disease. Read her story here: www.icr.ac.uk/research-and...

Lucia and Szen have been fundraising for the Institute of Cancer Research. Last weekend, they raised over £2872.49 and wish to thank those who donated so many items to sell at their stall. You are amazing! For anyone wishing to contribute directly: www.justgiving.com/fundraising/...

There is something powerful about the @londonmarathon.bsky.social The theme music makes us nostalgic, the costumes make us smile and the stories make us emotional. Especially gratetul to Mandy supporting our continued work at @icr.ac.uk Read more👇 oncogeneresearch.org/icr-festival-t… #LCSM

I’m excited to share our new paper in Genome Biology, where we show SMARCA4 protects against genome instability at G4 sites, using analysis of double-strand break mapping and whole genome sequencing. It has been a really interesting and collaborative project! link.springer.com/article/10.1...

The SMARCA4 subunit of the SWI/SNF complex prevents genome instability at G quadruplexes - Genome Biology

Background G-quadruplex (G4) structures are secondary structures that can form in guanine-rich single stranded DNA sequences. These play important roles in biological processes such as regulation of g...

link.springer.com

Best of luck to everyone taking on the #LondonMarathon today! Thank you to all our amazing #TeamICR runners for your dedication and support! We'll be cheering you on at mile 13! 🎽👟🏅